Oklo

Q2 FY2026 EarningsQ2 FY26 revenue reached $1.21M, significantly beating the $71.8K consensus due to the integration of recent acquisitions. GAAP EPS was -$0.28, missing the -$0.16 consensus as operating losses widened to -$73.2M (vs. -$48.5M expected) on aggressive R&D scaling and acquisition-related costs. Strategic progress remained robust, highlighted by the Groves Isotope Test Reactor achieving first criticality in August 2026, though high cash burn for infrastructure and HALEU procurement remains a key focal point for investors.